US Pharma MarketingIn a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a lack of substantive evidence supporting their benefits and safety.
FDA panel endorses broader use of certain peptides
In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of four peptides despite a lack of substantive evidence supporting their benefits and safety.
Source: BioPharma Dive